Lipoprotein(a) screening in patients with premature myocardial infarction: Clinical role and impact on decision-making

Aim: The association between elevated lipoprotein(a) (Lp(a)) levels and the incidence of the atherosclerotic cardiovascular disease is well established. However, evidence for its clinical role in patients with premature coronary artery disease remains limited. We aimed to elucidate the role of the Lp(a) screening in patients with premature myocardial infarction, to assess its impact on the clinical decision-making and patients’ management.